Intech Investment Management LLC Increases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Intech Investment Management LLC lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 120.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,055 shares of the company's stock after purchasing an additional 44,208 shares during the quarter. Intech Investment Management LLC's holdings in Amneal Pharmaceuticals were worth $642,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMRX. JPMorgan Chase & Co. grew its stake in shares of Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after purchasing an additional 378,136 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals in the 4th quarter worth approximately $2,946,000. Polar Asset Management Partners Inc. raised its stake in Amneal Pharmaceuticals by 122.5% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock valued at $3,270,000 after buying an additional 216,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 16.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock valued at $11,689,000 after buying an additional 202,863 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Finally, Barclays raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $10.80.

Amneal Pharmaceuticals Stock Down 1.1 %

NASDAQ:AMRX traded down $0.09 during mid-day trading on Thursday, hitting $8.27. 1,153,105 shares of the company traded hands, compared to its average volume of 1,346,821. The stock's fifty day moving average price is $8.42 and its 200-day moving average price is $8.37. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -12.16 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the previous year, the business posted $0.14 EPS. Equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. This trade represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,240,000 shares of company stock worth $43,754,000. 26.56% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.